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Abstract 
 
The conversion of cellular prion protein (PrPc), a GPI-anchored protein, into a protease-
K-resistant and infective form (generally termed PrPsc) is mainly responsible for 
Transmissible Spongiform Encephalopathies (TSEs), characterized by neuronal 
degeneration and progressive loss of basic brain functions. Although PrPc is expressed 
by a wide range of tissues throughout the body, the complete repertoire of its functions 
has not been fully determined. Recent studies have confirmed its participation in basic 
physiological processes such as cell proliferation and the regulation of cellular 
homeostasis. Other studies indicate that PrPc interacts with several molecules to 
activate signaling cascades with a high number of cellular effects. To determine PrPc 
functions, transgenic mouse models have been generated in the last decade. In 
particular, mice lacking specific domains of the PrPc protein have revealed the 
contribution of these domains to neurodegenerative processes. A dual role of PrPc has 
been shown, since most authors report protective roles for this protein while others 
describe pro-apoptotic functions. In this review, we summarize new findings on PrPc 
functions, especially those related to neural degeneration and cell signaling.  
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ADAM: A Disintegrin and Metalloproteinase protein 
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CD: Central Domain of PrPc 
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GPI: Glycosyl-Phosphatidylinositol 
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Hsp60: Heat Shock Protein 60 
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PrPc: Cellular Prion Protein 
PRNP: Cellular Prion gene  
PrPsc: Scrapie form of PrPc, used to term infectious Prion forms 
SOD: Superoxide Dismutase 
Sho: Shadoo 
STI-1: Stress-Inducible Protein 1 
TSE: Transmissible Spongiform Encephalopathy  
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1. Introduction  
 
Transmissible Spongiform Encephalopathies (TSEs), which include Creutzfeldt-Jackob 
disease (CJD) in humans (Bruce et al., 1997; Collinge et al., 1996; Hill et al., 1997), 
Bovine Spongiform Encephalopathy (BSE) in cows (Wells et al., 1987), Scrapie in 
sheep (McGowan, 1922), or Chronic Waste Disease (CWD) in elk and deer (Wells et 
al., 1987), are infective diseases promoted by the re-folding of the host-protein cellular 
prion (PrPc) into a pathological, protease K-resistant and -sheet-enriched form (PrPsc 
or PrPres) (Prusiner, 1982). Despite extensive neuropathological studies into prion 
diseases, it is still unclear whether the toxicity of PrPsc or the loss-of-function of intrinsic 
PrPc is responsible for the neurodegeneration observed in these pathologies. We 
devote this review specifically to PrPc functions in intercellular signaling and 
neurodegeneration. Readers interested in immunological or other aspects of PrPc 
biology (e.g., transmission, detection, analyses of human diseases, etc.) are referred to 
recent reviews (e.g., (Aguzzi et al., 2008a; Aguzzi et al., 2007; Aguzzi et al., 2008b; 
Linden et al., 2008)).    
 
In humans, PRNP is located on chromosome 20 and comprises two exons (Basler et 
al., 1986). Transcription of the second exon gives rise to the complete PrPc protein 
(Puckett et al., 1991). The structure of several mature PrPc proteins in mice, cattle, 
humans, and Syrian hamsters is very similar. PrPc is an extracellular protein that 
contains two glycosylation sites and is enriched in -helix domains (Pan et al., 1993; 
Riek et al., 1996), which are anchored to the detergent-resistant areas of the plasma 
membrane by a glycosylphosphatidylinositol (GPI)-link (Prusiner, 1998b). The protein 
has a long, flexible N-terminal tail (residues 23–128), three α-helices, and a two-
stranded antiparallel β-sheet flanking the first α-helix. This flexible N-terminal tail is 
  
present in most of the animal species studied, except deer and elk, and contains series 
of four or five repeats of eight amino acids (PHGGGWGQ). The second domain of PrPc 
is the central domain (CD), which includes a sequence of positively charged residues 
(termed Charge Cluster or CC) and a hydrophobic region (HR) (Prusiner, 1998b) (See 
Fig. 1). The last domain or C-terminal globular domain (Donne et al., 1997; Riek et al., 
1997) contains the -helix and two parallel stranded -sheets (Riek et al., 1996). PrPc 
presents at least three distinct topological orientations: the fully extracellular form (or 
(sec)PrP) (Holscher et al., 2001), and two transmembrane isoforms (called Ntm-PrP 
and Ctm-PrP) with opposite sequence orientations with respect to the lumen of the 
endoplasmic reticulum (Hegde et al., 1998). 
  
The nucleic sequence of PrPc has been strongly conserved throughout evolution in 
mammals (Rivera-Milla et al., 2006), especially in those regions that encode flexible 
domains of the protein (Wopfner et al., 1999). However, alignments of human and 
mammalian PRNP sequences indicate that codons located between residues 90 and 
130 influence the transmissibility of prions in mammals, including humans (Schatzl et 
al., 1995). In addition, some paralogue genes have been described in chicken, 
amphibians, reptiles and fish (Gabriel et al., 1992; Simonic et al., 2000; Strumbo et al., 
2001; Suzuki et al., 2002) 
 
2. Tissue and cellular expression of PrPc: from the whole organism to the 
neuronal synapse. 
 
In mammals, PrPc is expressed in several tissues, such as secondary lymphoid organs, 
heart, and neural tissue (see (Ford et al., 2002; Linden et al., 2008; Miele et al., 2003) 
for examples), with lower levels found in kidney and liver (Miele et al., 2003; Tichopad 
et al., 2003). In the brain, maximal Prnp mRNA expression is observed in the adult 
  
neocortex and cerebellum. At the cellular level, Prnp is expressed in various neuronal 
populations of the hippocampus, thalamus and neocortex (Bailly et al., 2004; Harris et 
al., 1993) and in glial cells (Ford et al., 2002; Laine et al., 2001; Moser et al., 1995; 
Radovanovic et al., 2005). In neurons, PrPc is predominant in axons and dendrites, 
excluded from synapse vesicles, and detected in endosomal compartments (Mironov et 
al., 2003). PrPc has also been identified in elongating axons (Sales et al., 2002). 
However, its presence and its putative role at the synapse are controversial (Fournier 
et al., 1995; Laine et al., 2001; Vassallo and Herms, 2003). For example, in CJD 
patients, an abnormal form of PrPc accumulates at synaptic terminals (Kitamoto et al., 
1992), which suggest that loss of natural function of PrPc or PrPc -mediated processes 
at the synaptic terminals is responsible for neuronal dysfunction and degeneration in 
this disease (Kitamoto et al., 1992). How PrPc participates in synaptic transmission is 
unknown. However, several explanations have been proposed. PrPc may help 
neurotransmitter release, as reported at the neuromuscular junction (Re et al., 2006). 
In this regard, the vesicle-associated protein Synapsin Ib has been reported to interact 
with PrPc; which may supports this hypothesis (Spielhaupter and Schatzl, 2001). In 
addition, PrPc, by Cu2+ binding, may participate in the control of calcium flux and redox 
stage of the presynaptic terminal (Vassallo and Herms, 2003). Lastly, pioneering 
electrophysiological studies (using PrPc knockout slices) by Collinge established that 
PrPc participates in long-term potentiation (Collinge et al., 1994; Curtis et al., 2003; 
Maglio et al., 2006). More recently, it has been shown that the absence of PrPc alters  
the expression of several neurotransmitter receptors (see (Maglio et al., 2004; Rangel 
et al., 2007) for examples). Thus, Prnp0/0 mice show  increased neuronal excitability as 
well as enhanced glutamate excitotoxicity by modulation of NMDA as well as kainate 
receptors (Khosravani et al., 2008b). PrPc therefore has distinct functions during 
neurotransmitter release and receptor synthesis in neural transmission. Furthermore, 
among these functions in neurotransmission, an additional role in synapse formation 
and maintenance cannot be ruled out, since PrPc interacts with structural scaffold 
  
proteins at the synapse (e.g., PSD95) (Yehiely et al., 1997) and recent studies point to 
parallel scaffolding functions in other cell types during cell-cell interactions (Morel et al., 
2008). These data indicate that the structural effects of neural PrPc during synapse 
formation and stabilization may occur in intrinsic or extrinsic ways. Intrinsic Prnp 
expression is developmentally regulated (Miele et al., 2003) and takes place 
postnatally in neural tissue (Steele et al., 2006), especially during the fate restriction of 
multipotential cells towards the neural lineage (Mouillet-Richard et al., 1999), stages 
characterized by neuronal polarization and synapse formation. Conversely, 
extracellular PrPc may act via specific receptors in neighboring neurons to promote 
synapse formation and neuronal maturation (Graner et al., 2000; Kanaani et al., 2005). 
In this regard, PrPc is considered a dynamic cell-surface platform for the assembly of 
signaling molecules which may participate in neuronal processes, including neuronal 
differentiation (see (Linden et al., 2008) for additional review). 
 
3. The arise for physiological functions of PrPc 
 
The repertoire of physiological functions of PrPc is beginning to be elucidated. Indeed, 
several studies report numerous physiological processes associated with PrPc or PrPc -
mediated events. Some of these are summarized below. 
 
3.1. PrPc and Copper homeostasis: more than simple binding or a “kiss and run” 
phenomenon. 
 
By using synthetic peptides, several authors have reported that the OR region of PrPc 
binds Cu2+ , and to a lesser extent Cu+, thereby modulating its intracellular levels (e.g., 
(Hornshaw et al., 1995a; Hornshaw et al., 1995b)). Indeed, synaptosomal fractions 
have revealed that the amount of copper in the brain of  PrPc knockout mice is lower 
than in wild-type (WT) counterparts (Herms et al., 1999). However, other studies have 
  
not reproduced these results, since subcellular fractions of WT and PrPc knockout mice 
show equal Cu2+ level and Cu/Zn SOD and CitC oxidase activity  (Waggoner et al., 
2000). Far from these discrepancies, in vitro cerebellar neuron cultures revealed that 
PrPc modulates oxidative stress through regulating Superoxide Dismutase-1 (SOD-1) 
activity in a Copper-dependent manner (Brown et al., 1997b; Sorenson, 2001). 
Experiments using recombinant PrPc and PrPc immunoprecipitated from brain tissue 
has postulated SOD activity as an intrinsic property of the PrPc protein (Brown et al., 
1999), although other authors were unable to find this activity in vivo (Hutter et al., 
2003). Interestingly, at the synaptic cleft, Cu2+ regulation by binding to PrPc has been 
associated with the regulation of redox levels to facilitate neural transmission (Brown et 
al., 1997a; Herms et al., 1999). However, PrPc functions appear to be more diverse 
than a single redox control by PrPc-Cu2+ binding in the cell or in the synapse, since 
PrPc-Cu2+ in vitro binding promotes clathrin-mediated endocytosis (Cheng et al., 2006; 
Haigh et al., 2005; Pauly and Harris, 1998). This observation suggests that PrPc or 
PrPc-Cu2+ binding is involved in the turnover of several receptors at the plasma 
membrane. This process is probably mediated by the low-density lipoprotein receptor-
related protein 1 (LRP1) (Taylor and Hooper, 2007) in a dynamin-dependent manner 
(Caetano et al., 2008). The effects of PrPc-Cu2+ binding are diverse, and most require 
further detailed analysis. However, a common feature in these functions appears to be 
the maintenance of cellular homeostasis. 
 
3.2. PrPc ligands and intracellular signaling 
 
Numerous studies have determined several PrPc ligands but the function of most of 
these interactions is still unclear. Moreover, the results of these studies are not always 
reproducible. Most of the interactions have been determined by co-
immunoprecipitation, two-yeast assays or other biochemical techniques. Among the 
  
myriad of interactions described, Hsp60 (Edenhofer et al., 1996), STI1 (Zanata et al., 
2002), Bcl-2 (Kurschner and Morgan, 1995), and Grb2 (Spielhaupter and Schatzl, 
2001) have been proposed as PrPc ligands. However, only a small proportion of these 
related pathways are functional in a physiological context (see (Lee et al., 2003) or 
(Westergard et al., 2007) and (Linden et al., 2008) for reviews). Two in vitro studies 
demonstrate that PrPc binds to the laminin receptor 67K (Gauczynski et al., 2001) and 
the adhesion molecule N-CAM (Santuccione et al., 2005; Schmitt-Ulms et al., 2001), 
both transducing survival signals or promoting neurite outgrowth. In addition, PrPc 
mediates neuritogenesis in a laminin-mediated manner (Graner et al., 2000), thereby 
suggesting that the PrPc-laminin interaction is relevant for neuronal development and 
further plasticity-related mechanisms. Indeed, Prnp is overexpressed by cortical 
neurons during axon regeneration and sprouting (JADR et al., unpublished data). 
Conversely, some of the interactions described for PrPc are also associated with 
neurodegeneration in prion diseases. As an example, the interaction of this protein with 
the precursor of the laminin receptor (Rieger et al., 1997), or its interaction with 
glycosaminoglycans, such as chondroitin sulphate A/B, heparin and hyaluronic acid 
(Pan et al., 2002), have been postulated to facilitate the PrPc to PrPsc conversion in 
vitro (Wong et al., 2001). Whether these interactions play similar roles in vivo is 
unknown. 
 
Furthermore, several in vitro studies have addressed PrPc-mediated signaling (see 
(Westergard et al., 2007) for review). In this sense, we would like to remark two sets of 
studies with opens the notion of PrPc as a signaling molecule. In the first, using PrPc 
aggregation strategies, Mouillet-Richard and coworkers reported that PrPc-mediated 
signaling by P59Fyn kinase modulates cell survival in 1C11 cell line (Mouillet-Richard 
et al., 2000; Santuccione et al., 2005). This data is crucial since it linked the survival 
properties of PrPc to a specific signaling pathway. In this regard,  the yeast two-hybrid 
system pointed to Grb2 and other proteins as interactive partners in signal 
  
transduction, although this interaction has not been fully demonstrated in functional 
terms (Spielhaupter and Schatzl, 2001). The second set of studies was conducted by 
V.R. Martin´s group, who described the interaction of the Stress-inducible protein 1 
(STI1) with PrPc in neuronal hippocampal cultures (Lopes et al., 2005). These results 
are also important since ST1 is a co-chaperone located at the cell surface that binds 
PrPc, thereby inducing several responses in distinct types of cell, such as 
neuroprotection or neuritogenesis. Most effects are mediated through cAMP-dependent 
protein kinase A (PKA) and stress-related kinase ERK1/2 signaling (Lopes et al., 
2005). For the intracellular transduction of PrPc-STI1-mediated signaling, endocytosis 
of PrPc is required (Americo et al., 2007; Caetano et al., 2008). For this reason, a 
strong correlation between PrPc trafficking alterations and prion pathologies have been 
suggested in other studies (Borchelt et al., 1992; Kiachopoulos et al., 2004; Pimpinelli 
et al., 2005; Shyng et al., 1995). Lastly, a recent study has reported PrPc-independent 
functions of STI1 in cell proliferation (Arruda-Carvalho et al., 2007). However, this 
observation appears to be only specific to retinal cells, although the interaction of STI1/ 
PrPc takes places in most neurons as well as malignant glial cells.   
 
3.3 PrPc, cell cycle regulation and differentiation: jumping the G1 phase 
 
The presence of PrPc is crucial for the proliferative stage of several subsets of cells 
along the body axis. However, the expression of this protein in proliferating cells differs 
and may explain the particular behavior of these cells in relation to PrPc expression. 
For example, PrPc expression in vitro leads to lymphoid cell proliferation (Cashman et 
al., 1990; Li et al., 2001) or promotes human hematopoietic cell renewal (Zhang et al., 
2006). In addition, PrPc is directly involved in tumor cell progression in several tissues. 
A specific isoform of PrPc is highly expressed during G1 phase in a human 
glioblastoma cell line (Kikuchi et al., 2002). Indeed, in gastric cancer, PrPc mRNA and 
protein levels are overexpressed in diverse tumor cell lines (Liang et al., 2007). 
  
However, contradictory results using other neoplastic and viral-transformed cell lines 
show that PrPc expression in G1 correlates with growth arrest or terminal differentiation 
(Gougoumas et al., 2001; Kniazeva et al., 1997). These observations open the 
question as to whether additional mechanisms acting together with PrPc regulate cell 
proliferation and G1 transition. For example, a transcriptomic study by Satoh 
determined that PrPc knockout fibroblasts showed a decreased expression of  cell 
cycle-involved proteins such us cyclin D1, Eps8, and CD44 compared to control cells 
(Satoh et al., 2000).  
 
Neural tissue is an interesting case as PrPc is differentially regulated in proliferating 
cells. In mice, PrPc expression starts during development around embryonic day E8,5-9 
in postmitotic neurons (Miele et al., 2003) and around day E13,5-16,5 in specific non-
neuronal populations (Manson et al., 1992). In the adult, PrPc is not expressed by 
proliferating cells in the subventricular zone of the lateral ventricle (Steele et al., 2006). 
However, unpublished studies by our group indicate that adult oligodendrocyte 
precursors express PrPc (Fontana et al., unpublished data). As reported by Steele and 
coworkers, neural stem cell proliferation in the subventricular zone is positively 
regulated by increasing PrPc expression levels in Tg20-overexpressing mice. In 
contrast, proliferating cells in the hippocampus show lower proliferative rates in PrPc 
knockout mice, and no relevant effect of PrPc expression is observed in the 
proliferation of hippocampal progenitors, since enhanced expression of this protein 
does not correlate positively with increased proliferation with respect to WT mice 
(Steele et al., 2006). Surprisingly, previous in vitro studies showed that PrPc-deficient 
neural cell lines derived from embryonic hippocampus display higher proliferative rates 
than WT cells in culture (Kim et al., 2005). As indicated above, recent results from our 
group demonstrate PrPc expression in remnant oligodendrocyte progenitor cells 
located in the adult neural parenchyma that normally proliferate (Fontana et al., 
unpublished data). This particular population showed a higher proliferative rate in PrPc 
  
knockout than in WT or PrPc-overexpressing mice. Taken together, these observations 
suggest that PrPc has a cell-specific function in cell proliferation. Most probably, PrPc 
acts with other factor/s to modulate cell proliferation and differentiation. In this scenario, 
several questions remain unanswered. Does increased expression of PrPc in 
overexpressing mice affect proliferating cells in the subventricular zone that do not 
express PrPc in these mice? And more relevantly, if increased PrPc expression in 
neuronal cultures potentiates neuronal differentiation, polarization and synapse 
formation, does it increase cell proliferation in the subventricular zone? (Kanaani et al., 
2005). Answers to these questions have not been given, but we can hypothesize that 
PrPc acts as an “inducer” of the intrinsic proliferative properties of these cells in 
“neuronal niches”, probably by forming part of or acting on a “neurotrophic” complex, 
and that PrPc expression inhibits cell proliferation in other neural cell types that do not 
show this “neurotrophic” complex. In this regard, a recent study reports a dual role of 
PrPc in cell proliferation and cell polarization (e.g., in the formation of desmosomal 
junctions) in epithelial cells (Morel et al., 2008), thereby expanding the functions of this 
protein in cell proliferation and differentiation. 
 
3.4.- Emerging roles of PrPc modulating A deposition and Alzheimer’s disease 
progression 
 
During several years, several studies showed by different ways a putative interaction 
between prionopathies and Alzheimer´s disease (AD) (e.g., (Checler and Vincent, 
2002)). Thus coexistence of PrPsc and A(1-42) in the same amyloid plaque has been 
described in patients with Creutzfeldt-Jakob or Gerstmann-Straussler-Scheinker 
diseases (e.g., (Ferrer et al., 2001; Preusser et al., 2006; Tsuchiya et al., 2004). Thus 
several studies aimed to determine a putative interaction between A deposition and 
PrPc functions. For example an study of Debatin and coworkers reported the co-
  
occurrence of pathological changes typical for sporadic CJD and Alzheimer´s disease 
in combination with the inverse association between accumulation of A and PrPsc in a 
subgroup of sporadic CJD patients as indicative of pathways involved in the generation 
or clearance of A and PrPsc in a subgroup of sporadic CJD patients (Debatin et al., 
2008). This study was in contrast results obtained in mouse models were the 
inoculation with PrPsc increased A deposition in AD models (Baier et al., 2008) or  
studies reporting increased A accumulation in PrPc mutant models (Schwarze-Eicker 
et al., 2005). In a first study, Parkin and coworked determined that PrPc modulated 
BACE1 activity being a negative regulator of A production (Parkin et al., 2007). Last 
month, a study of Landis et al., determined the interaction of PrPc with -amyloid 
oligomers (Lauren et al., 2009). In this study, the authors claimed that PrPc is a 
mediator of amyloid--oligomer-induced synaptic dysfunction and A-deposition, and 
PrPc-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease 
(Lauren et al., 2009). Thus point might reinforce the data of Debatin et al., concerning 
the mechanism of clearance of A deposits. Thus, the conversion between PrPc and 
PrPsc, may interfere with this clearance by a putative reduction of PrPc in brain 
parenchyma since this process is independent of PrPsc as indicated by Lauren et al. 
(Lauren et al., 2009). Indeed, the study opens the notion that additional factors than 
PrPc might also affects AD progression and to whether PrPc-mediated function affects 
the phosphorylation of Tau an additional hallmark of the AD not analyzed in the study 
of Lauden and coworkers. On the other hand, a function of PrPc inducing A 
oligomerization may explain the studies of Schwarze-Eicker et al., and Baier et al., (Fig. 
2). In this respect, it is well khown that PrPc bind amyloid fibrils (see (Li et al., 2007b) 
for comments). 
 
4. Prnp knockout mice: the arise for its functions in mice models 
 
  
To ascertain the putative roles of PrPc, diverse groups have generated several mouse 
models that lack PrPc expression and carry several copies of the Prnp gene. More 
recently, mice that express a number of modified PrPc proteins have also been 
produced. All these studies have opened new avenues of research as various 
phenotypes observed in some of these mice were unexpected. In addition, recent 
studies have revised previous descriptions for some of these rodents, especially those 
first produced (see below). 
  
4.1. Prnp-deficient mice 
 
The generation of two lines of mice by disrupting Prnp expression was carried out in 
the early 1990s: Zürich I (outbred) (Bueler et al., 1992) and Edinburgh I (inbred) 
(Manson et al., 1994) lines (see (Weissmann and Aguzzi, 1999) for review). Prnp-
knockout mice are resistant to prion infection (Bueler et al., 1993) but surprisingly do 
not show major phenotypical defects. However, it was finally demonstrated that 
Edimburgh Prnp-knockout mice show alterations in circadian rhythms (Tobler et al., 
1996) and cognitive deficits (Criado et al., 2005). In addition, both lines showed deficits 
in synaptic transmission (Collinge et al., 1994; Herms et al., 1995) and increased 
sensitivity to oxidative stress (Brown et al., 2002). Recent studies indicate that these 
mice also show increased susceptibility to glutamate excitotoxicity (Khosravani et al., 
2008a; Rangel et al., 2007; Walz et al., 1999; Walz et al., 2002) as a result of changes 
in the expression of glutamate receptor subunits (Khosravani et al., 2008a; Lledo et al., 
1996; Rangel et al., 2007). More recently, a conditional knockout of PrPc has been 
generated (Mallucci et al., 2002). These mice do not show the behavioral alterations of 
infected mice unless PrP aggregates are formed (Mallucci et al., 2003; Mallucci et al., 
2007).  
 
4.2. Other PrPc mutant mice: the puzzle of functions increases. 
  
 
Following the Zürich I and Edinburgh I strains, other mouse models were generated. 
The Nagasaki I line was developed in 1996. These mice show selective death of 
Purkinje Cells (PCs) and subsequent progressive cerebellar-associated ataxia 
(Katamine et al., 1998; Sakaguchi et al., 1996). The Rcm0 line (Moore et al., 1999; 
Silverman et al., 2000) displays a large deletion in the Prnp gene and unexpectedly 
overexpresses a homolog PrPc protein, called Doppel (Dpl, from the German double). 
Rcm0 mice show severe PC death and ataxia. Finally, a Zürich II line, generated in 
2001, was found to be very similar to Rcm0 regarding the Prnp deletion and the 
phenotypic ataxic syndrome (Rossi et al., 2001). These studies led to the discovery of 
Dpl and it has been proposed that the functions of this protein are opposed or 
complementary to those of PrPc. In fact, Dpl-mediated toxicity of PCs is reversed by the 
introduction of WT PrPc (Yamaguchi et al., 2004). However, the role of Dpl is not clear 
since it shows low expression in adult brain and the studies performed to date have 
focused on its roles during development and in other organs (Behrens and Aguzzi, 
2002) and also its functions in prion pathogenesis (Behrens et al., 2001; Mo et al., 
2001)  
 
Dpl protein shares with PrPc the C-terminal portion of the molecule but lacks the OR 
and CD, although it conserves the GPI anchor (Moore et al., 1999). On the basis of 
these observations, several studies were directed to analyzing the phenotype of mice 
expressing truncated forms of PrPc (lacking some portions of the N-terminal domains). 
As expected, in comparison with Dpl mice, in N-terminal truncated mice, the neocortex 
as well as other brain regions were preserved, but the cerebellum was strongly affected 
and cerebellar neurons showed degeneration (Li et al., 2007b; Shmerling et al., 1998). 
Whether these effects in Dpl mice are specifically associated with the cerebellum is 
unknown, but differential expression of PrPc or Dpl together with the presence of 
putative ligands/receptors might be involved. In this regard, histoblots have revealed 
  
that either Fc-labelled Dpl or PrPc bind specifically to cerebellar granule neurons 
(CGNs) (Legname et al., 2002), which may explain why the cerebellum suffers 
degeneration in Dpl-mediated degeneration while other brain structures remain healthy. 
 
Prnp knockout mice overexpressing the C-terminal portion of PrPc (lacking OR and CD) 
of the N-terminal domain (F35 mice) display CGN death, white matter pathology and 
a progressive and early lethal ataxic phenotype termed Shmerling syndrome 
(Radovanovic et al., 2005; Shmerling et al., 1998). PCs present no signs of 
degeneration because of enhancer-mediated splicing that prevents F35 expression in 
these neurons (Shmerling et al., 1998). However, targeted-PC expression of the F35 
construct by a specific promoter induces PC death and ataxia (Anderson et al., 2004; 
Flechsig et al., 2003). Similarly to Dpl-mediated degeneration, Shmerling syndrome is 
rescued by reintroducing the full-length Prnp (Shmerling et al., 1998). However, it has 
been proposed that myelin pathology induced by N-terminally truncated PrPc acts 
through independent mechanisms, in contrast to CGN depletion (Radovanovic et al., 
2005). Recent studies have shown that overexpression of PrPc devoid of CD or a 
fragment of CD (residues 105-125) in PrPc knockout mice promotes an exacerbated 
ataxic syndrome, causing lethality at approximately postnatal day 20 (Baumann et al., 
2007; Li et al., 2007b). More in-depth studies using these knockout mice would be 
useful to elucidate the physiological functions of the domains of PrPc, and also to 
improve our understanding of the putative signaling pathways involved in prion-related 
pathologies. 
           
4.3. PrPc expression and prion pathology 
 
The generation of mice devoid of PrPc implied a reinforcement of the "Protein only 
hypothesis", proposed by Stanley Prusiner in 1982 (Prusiner, 1982), since knockout 
  
mice showed prion infection resistance and could not replicate prion infection 
(Brandner et al., 1996; Bueler et al., 1993). In 2003, it was reported that PrPc depletion 
in mice stops scrapie-mediated neuronal degeneration (Mallucci et al., 2003), and also 
recovers behavioral and cognitive symptoms (Mallucci et al., 2007). In addition, PrPsc 
does not infect neurospheres derived from PrPc knockout mice in vitro (Giri et al., 
2006), and Prnp null mice are re-sensitized to prion infection even when several amino-
truncated PrPc constructs are expressed (Aguzzi and Heikenwalder, 2006; Aguzzi and 
Polymenidou, 2004; Fischer et al., 1996; Flechsig et al., 2000). Regarding the 
presence of PrPc for prion transmission, GPI-anchoring has been proposed as a key 
factor in scrapie infection; in fact, mice lacking GPI fail to reproduce clinical scrapie, 
although amyloid deposition is present (Chesebro et al., 2005). These studies 
demonstrate that the presence of PrPc is indispensable for prion pathologies and that 
the interaction of this protein with the plasma membrane contributes to 
neurodegeneration. Despite of this helpful data, more simple models altering certain 
PrPc properties (like the expression levels) could improve our understanding of PrPsc 
toxicity and transmissibility.   
 
In this sense, it has been reported that modulation or restriction of PrPc expression in 
some prion models has aroused as an important tool focused on the understanding of 
prion infection/invasion mechanisms. For example, generation of Prnp knockout mice 
with restricted PrPc expression to B or T cells have been useful to elucidate important 
questions in prion neuroinvasion (Brandner et al., 1999; Raeber et al., 2001). In 
addition, these models could be complemented using neuroendocrine cell lines which 
have been proposed as models for the studying of physiological mechanisms of PrPsc 
counteracting (Aguib et al., 2008). In consequence, the generation of neuronal lines 
has supposed new models for the in vitro study of the PrPc-PrPsc interaction. For 
example, a neural line derived from Zürich I mice which do not express Dpl have 
shown neuronal features (Kim et al., 2005). Thus, it would be feasible to induce 
  
differential levels of PrPc expression or to alter other important factors (like PrPc 
cytoplasm/membrane localization, trafficking or glycosilation) in order to study how 
PrPsc invasion/toxicity is modulated. In this regard, we would point out certain studies 
that revealed interesting data about PrPc expression and properties; in fact, further 
studies based on these findings could be helpful to understand the progression of prion 
diseases. For example, in vitro experiments showed that the inhibition of PrPc 
glycosilation promoted the formation of PrPsc-like molecules (Ma and Lindquist, 1999), 
and other PrPsc-like molecules accumulates in aggresomes (Cohen and Taraboulos, 
2003). In addition, the study of the cytosolic form of PrPc have provided new insights 
regarding which signaling pathways could be presumably involved in prion disorders; 
for example, in aged transgenic mice overexpressing PrPc, mitochondrial localization of 
PrPc promotes neuronal apoptosis (Hachiya et al., 2005) and cytosolic PrPc failed to 
rescue Bax-induced cell death in yeast (Li and Harris, 2005), supporting the toxic 
properties of cytosolic PrPc in neurons (Rambold et al., 2006). However, it is necessary 
to take into account which of these related pathways are directly implicated in the “real” 
human or animal prion disease (Chiesa et al., 2005). In the other hand, prion pathology 
triggers primarily dysfunction and activation of glial cells rather than neuronal death, in 
contrast with other degenerative disorders (Prusiner, 1991; Prusiner, 1998a). In 
consequence, several studies have focused in the study of the role of glial cells in prion 
diseases. As mentioned, although neuronal apoptosis is important in prion-associated 
neural degeneration (Gray et al., 1999), microglial/astroglial recruitment is crucial for 
the progression of the disease (Baker et al., 2002; Depino et al., 2003; Giese et al., 
1998; Giese and Kretzschmar, 2001; Marella and Chabry, 2004; Schultz et al., 2004). 
In consequence, transgenic models such as PrPc knockout mice that ectopically 
overexpress Dpl have elucidated important issues in the mechanisms of glial activation. 
This study strongly suggest that ectopic Dpl expression in the absence of PrPc is 
actively involved in the glial-cell activation in the brain the glial cell activation was 
notable well before the onset of the Purkinje cell degeneration in these mice. (Atarashi 
  
et al., 2001). However, more refined in vitro studies modeling neuronal degeneration 
and glial proliferation would be useful to strongly link morphological and histological 
features observed in postmortem brains with specific signaling pathways related in 
neuronal degeneration and survival.  
       
5. Dissecting PrPc domains and cell death: the N-terminal domain 
 
The N-terminal domain of PrPc is a flexible "tail" compared to the C-terminal portion 
(Donne et al., 1997; Riek et al., 1996), N-terminal fragments are present in brains 
affected by scrapie and correlate with the presence of protease-resistant PrPc forms 
(Pan et al., 2005). In addition, aberrant N-terminal truncated forms of PrPc tethered to 
the cell membrane alter the response to oxidative stress and become protease-
resistant (Zeng et al., 2003). Moreover, processing of the putative N-terminal 
transmembrane fragment could be determinant in neurodegenerative diseases, since 
mice expressing a PrP variant (mutation that alters topological orientation) promote 
neuronal degeneration (Hegde et al., 1998; Stewart et al., 2001). The overexpression 
of an N-terminal truncated PrPc lacking the OR region in an immortalized PrPc-deficient 
cell line promotes cell death through the caspase-3 pathway. This effect correlates with 
SOD inhibition, thereby suggesting a relationship between oxidative stress and the cell 
death triggered by the PrPc-lacking the OR (Sakudo et al., 2003). Accordingly, the 
insertion of three octarepeats alters the conformation of PrPc, thereby promoting 
greater cell susceptibility to oxidative insults in vitro (Yin et al., 2006). Indeed, PrPc 
lacking the OR fails to undergo oxidative-mediated -cleavage, thereby promoting an in 
vitro increase in cell susceptibility to oxidative radicals (Watt et al., 2005). In PrPc 
knockout mice, the OR domain contributes to pathologies induced by N-terminal 
truncation. In fact, OR-inserted PrPc does not completely overcome the F35 ataxic 
syndrome (Li et al., 2007c). On the basis of these observations, these authors 
  
concluded that OR domain integrity is crucial to the prevention of F35-evoked gain-of-
function.  
 
6. Dissecting PrPc domains and cell death: the Central Domain 
 
Like the OR, the Central Domain (CD) of PrPc plays a decisive role in cell homeostasis. 
This domain is formed by a positively-charged cluster (from 95 to 110 residues) and a 
hydrophobic transmembrane region (from 112 to 133) located in the N-terminal domain 
of the protein (Fig. 1). Two specific sequences are crucial to membrane topology. 
Residues 110 to 135 confer hydrophobic properties to PrPc, and mutations in this part 
alter endoplasmic reticulum regulation and promote cell degeneration (Hegde et al., 
1998; Stewart et al., 2001) while the Stop Transfer Effector sequence (residues 103 to 
111) directs PrPc chains to the transmembrane (Yost et al., 1990). Furthermore, the 
transmembrane part of PrPc holds specific residues that regulate chain orientation 
when the protein is anchored to the cell membrane (Ott et al., 2007). All the above 
observations point to the relevance of the CD in PrPc transmembrane signaling and in 
PrPc to PrPsc conversion.    
 
The central sequence of the CD (residues 105-125 in mice and 106-126 in humans), 
which is the most conserved part of PrPc, is essential for the biological functions of the 
protein. It has been extensively reported that peptides mimicking this part of PrPc 
promote neurotoxicity in neuronal cell cultures (Forloni et al., 1993) because of their 
self-aggregative properties. However, these studies are subject to debate since the 
requirement of PrPc expression for synthetic peptide toxicity is controversial (see for 
example (Brown, 2000; Fioriti et al., 2005; Gavin et al., 2005; Kunz et al., 1999; Singh 
et al., 2002)). 
 
  
N-terminally truncated constructions, like F35 or Dpl protein, lack residues 105-125 
(Luhrs et al., 2003; Mo et al., 2001; Shmerling et al., 1998). F35 and Dpl 
overexpression promotes neural cell death in several mouse models, thereby 
implicating  the 105-125 region in survival signaling and indicating that its absence 
promotes the activation of several death-related pathways. Moreover, mice lacking the 
105-125 (PrPCR) region develop an exacerbated ataxic syndrome (Li et al., 2007b), 
similar to that observed in F35, PrPCD and Dpl models. These three "PrPc-like" 
proteins appear to trigger the same death pathways; the histological characteristics of 
the degenerating cerebellum in these mice are similar (regarding CGN/PC death, white 
matter vacuolization), as are their biochemical properties (membrane attachment and 
vesicular trafficking). A copy of Prnp rescues these neurodegenerative processes, 
thereby pointing to a common ligand-mediated toxicity mechanism rather than a 
misfolding protein (Baumann et al., 2007; Li et al., 2007b; Shmerling et al., 1998).  
However, to some extent, the toxic activity of PrPsc and the protective activity of PrPc 
are interconnected by  the HR region (Rambold et al., 2008). Using in vitro methods, 
these authors described that the HR plays a key role in the formation of PrPc dimers, 
which correlate with its neuroprotective role, and, more relevantly, that in scrapie-
infected cells the number of PrPc dimers decrease in parallel with the loss of resistance 
to stress (Rambold et al., 2008). Although performed in vitro, this study is one of the 
first descriptions of a direct relationship between the protective functions of PrPc and 
scrapie-mediated neurotoxicity and it provides new insight into the functions of the HR 
domain. 
 
7. Ligands for the CD and neural cell death 
 
N-terminal truncated PrPc and Dpl mice display a large degree of neurodegeneration. 
Biochemical studies have shown that Dpl and F35 are glycosylated and membrane-
  
located like native PrPc (Behrens and Aguzzi, 2002), thereby suggesting a "non-
prionic" mechanism of degeneration. Interestingly, the C-terminal fragment of PrP 
(residues 121-231) is converted to a -enriched structure in a specific in vitro system 
(Hornemann and Glockshuber, 1998); however, no “scrapie-like” PrPc forms have been 
found in any Prnp knockout or F35 mice. These observations suggest that the 
pathology of Dpl/F35 models is caused by the absence of natural PrPc functions.  
 
Studies using F35 mice, Shmerling et al., as Moore et al. using Dpl-overexpressing 
mice, argued the similarities between the two " PrPc-like" proteins, and proposed that 
the overexpression of these forms might arrest a putative ligand (LPrP) required for cell 
survival (Moore et al., 2001; Shmerling et al., 1998). It was also proposed that a " PrPc-
like" protein, termed "", binds to this ligand in a "low-affinity manner", partially 
replacing physiological PrPc functions in Prnp knockout mice. This hypothesis would 
explain why mice devoid of PrPc do not show neural degeneration (Shmerling et al., 
1998). Dpl/F35 hypothetically antagonizes this effect by acting as a dominant inhibitor 
and preventing PrPc-mediated signaling. In addition, Dpl/F35  trigger death pathways 
(Shmerling et al., 1998). This model has recently been completed with the generation 
of PrPc knockout mice overexpressing a PrPc isoform that lacks the CD (residues 94-
134), the  PrPCD line. These mice present an exacerbated lethal ataxic syndrome, 
which is counteracted by the introduction of the complete PrPc or PrPc protein devoid of 
the OR region (Baumann et al., 2007). PrPCD mice constitute a stabilized dominant 
negative, and the OR region stabilizes PrPc-PrPc receptor interaction, but does not 
contribute directly to signaling (Baumann et al., 2007) (see Fig. 3A). A similar model is 
the Prnp knockout mouse model that overexpresses a N-terminal truncated PrP lacking 
the most evolutionary conserved residues (105-125), which is known as the PrPCR (Li 
et al., 2007b). Like other mutants, these mice develop severe ataxia and similar 
histological characteristics as F35 and CD mice, and this phenotype is rescued by 
  
expressing supraphysiological levels of PrPc. All of these observations indicate that the 
105-125 region of PrPc underlies relevant neuroprotective properties, and that its 
absence triggers neurotoxic pathways that promote CGN death, cerebellar atrophy and 
white-matter degeneration (Li et al., 2007b). The model proposed by Li et al. differs 
from the previous models in several ways. However, all the models share PrPc binding 
to its putative receptor by two binding sites; one in the N-terminal and a second located 
in the C-terminal domain. Thus, in this model, PrPCR has a higher affinity than WT PrPc 
or F35/Dpl for the possible PrPc receptor (because of the amount of PrPc required to 
rescue the pathological phenotype). Furthermore, the toxicity of PrPCR  is dependent 
on its capacity to activate in a "pathological" form PrPc receptor when only C-terminal 
binding site is occupied (Li et al., 2007b) (see Fig. 3B). Despite this models have 
emerged as a reasonable explanation for the neuronal pathology induced by truncated 
forms of PrPc, today there is no evidence to strongly fix these hypotheses. Further 
experiments trying to report proteins that could perform “” or LPrP functions would be 
interesting to follow investigations in this way. If not, other hypotheses (like F35 could 
play a toxic role per se, independently of PrPc modulation) would arise as new models 
to focalize other kind of studies.   
 
8.- Is Shadoo the “” protein? 
 
A new gene named SPRN (shadow of prion protein) was described in 2003 (Premzl et 
al., 2003). SPRN comprises two exons, with the open reading frame (ORF) contained 
within exon 2, and codes for a protein of 130-150 amino acids named Shadoo (Sho, 
Japanese shadow) present in mammals as well as other vertebrates (Premzl et al., 
2004). In a recent study, Watts and coworkers, described that Shadoo shared 
protective properties with PrPc (Watts et al., 2007), and stated that Sho functions 
counteract neurotoxic effects of either Doppel or F35 (Watts et al., 2007). In this 
  
study, Sho expression is decreased after PrPsc formation, which may also decrease the 
neuroprotection and enhance the development of the disease in a loss of function 
hypothesis of the PrPc roles (Fig. 4). Whether, Shadoo is the “” protein warrant further 
study but especially studies in Sho-deficient mice are needed. More relevantly if we 
take into account that a null allele of SPRN has been associated with CJD (Beck et al., 
2008). 
 
9. Bcl-2/BAX and PrPc-truncated mouse models 
 
Little is known about the intracellular cascades that lead to cell death in N-terminal 
truncated PrPc mouse models. However, a protein similar to F35 is generated in the 
healthy human brain when PrPc is endoproteolized into 110/111 residues through 
ADAMs in a Protein kinase C (PKC)-dependent way, thereby generating a C-terminal 
fragment termed C1 (Cisse et al., 2005; Chen et al., 1995; Harris et al., 1993; Vincent 
et al., 2000; Vincent et al., 2001). A shorter fragment, within the OR region (residues 
90/91), the C2, is generated in pathological conditions and poor data have yet been 
provided about this cleavage (Chen et al., 1995). A recent study by Sunyach and co-
workers established that stable C1 expression, but not C2, sensitizes HEK293 to 
apoptotic stimuli like staurosporine and that this effect is fully dependent on p53 activity 
(Sunyach et al., 2007). Similarly, F35 mice show increased p53 phosphorylation 
during the pre-degenerate stage (76 days), as well increased activity of stress-related 
kinases such as ERK1/2 or p38 (Nicolas et al., 2007). Accordingly, p38 and MdM-2 
activate p53 and promote death in neuronal cultures in hypoxic conditions (Zhu et al., 
2002). Furthermore, lentiviral p53-mediated caspase-3 activation is delayed in BAX-
deficient CGNs (Cregan et al., 1999). All these data implicate p53 and other stress-
related proteins in cell death mediated by truncated forms of PrPc.  
 
  
Bcl-2 overexpression and BAX suppression have been extensively used to prevent  cell 
death in several pathologic situations; for example, Bcl-2 overexpression in vivo largely 
delays clinical onset in a Familial Amyotrophic Lateral Sclerosis model (Kostic et al., 
1997), and BAX suppression prevents neuronal depletion in a prion disease model 
(Chiesa et al., 2005). Consequently, four studies have recently reported that cell death 
in N-terminal truncated overpressing mice and in the Nagasaki line is regulated in a 
Bcl-2/BAX manner (Heitz et al., 2008; Heitz et al., 2007; Li et al., 2007a; Nicolas et al., 
2007) (see Table 1). Surprisingly, contradictory results have been obtained in the latter 
strain, regarding the contribution of BAX depletion to ataxic syndrome rescue (Dong et 
al., 2007; Heitz et al., 2007). Taken together, these findings indicate that Bcl-2/BAX 
regulation is not the only switch in neuronal death mediated by N-terminal truncation 
and that other pathways are involved in CGN and PC degeneration. In this regard, 
Miller and co-workers demonstrated  in CGN apoptosis (in vitro conditions), although 
Bcl-2/BAX regulation is present, additional caspase-independent signaling pathways 
are required to promote cell death (Miller et al., 1997). Consequently, CR mice are not 
recovered by BAX suppression, thereby suggesting that the predominant cell death 
pathway in this model is not mitochondrial-dependent (Li et al., 2007b). Thus, it would 
be of interest to evaluate the implication of BAX-independent regulation factors in 
neural death (Cheung et al., 2005) in these apoptotic (or necrotic) processes. 
 
10. Conclusions: the function of PrPc remains a mystery in the 21th 
century.  
 
The functions attributed to PrPc have increased steadily in recent years. However, a 
new finding opens up an unexpected avenue and increases the complexity of this 
protein. New experimental approaches have revealed novel functions of PrPc in 
processes such as cell proliferation and differentiation, cell homeostasis, and cell death 
  
and survival. In addition, the discovery of Doppel, and more recently Shadoo, opens up 
new fields of research, since the neural functions of PrPc in the healthy or damaged 
brain remain elusive.  
 
Although sometimes controversial, emerging data converge to support the generally 
accepted notion that PrPc plays a crucial role in regulating the basal homeostatic 
equilibrium of neurons. Indeed, the imbalance of PrPc expression (absence or 
overexpression) or changes in PrPc-mediated interactions with other partners may 
predispose neurons to programmed cell death. This point is relevant since the 
participation of PrPc in other neurodegenerative diseases, such as AD, has recently 
been described. Thus, in the light of new findings in deficient mice (e.g., higher 
susceptibility to several types of stress effectors), the modification of PrPc expression 
levels as a putative therapeutic intervention should be considered with care. 
Concerning cell homeostasis, from the first studies describing the contribution of the 
OR region to Cu2+ binding, new domains of the protein have been reported to be 
involved in the maintenance of low cell stress. Here we have reviewed recent studies 
demonstrating that various mouse models of PrPc acquire neurotoxic potential in the 
absence of PrPsc. However, the most devastating effects are observed in mutant mice 
lacking the CR (including some residues of the HR) of the PrPc sequence. In addition, 
the HR region is involved in endoplasmic reticulum regulation and its absence 
promotes cell degeneration. The question remains as to why this region induces these 
effects. Recent results indicate that the HR region promotes the dimerization of PrPc, 
thereby increasing the stress-protective activity of the protein. The data available 
indicate that the unfolded pathogenic form of PrPC affects cell survival by blocking the 
formation of these dimers, thereby decreasing the natural neuroprotective functions of 
PrPc, and by direct neurotoxic effects. In parallel, these effects may also be 
exacerbated by the conversion of the intrinsic PrPc to PrPsc. These results should be 
corroborated in vivo especially in scrapie-inoculated mice lacking the HR domain in 
  
asymptomatic stages, but more relevantly, in conditional expression mouse models 
lacking distinct regions of the CD. However, we cannot rule out that other unknown 
factors or ligands could also play a parallel role in modulating the neurodegenerative 
phenotype in these mice since mice lacking particular sequences of the CD of PrPc 
show distinct viability (ranging from weeks to months). In addition, both apoptotic and 
non-apoptotic processes are present in these mice.  
 
In the search for cues, could Sho be considered the “” protein? Studies in Sho-
deficient mice are required to answer this question. Also, does PrPc or Sho modulate 
neurotrophic signaling by interacting with neurotrophic receptors or by modulating their 
intracellular signaling cascades? These are additional unsolved questions. These new 
studies demonstrate that the biological tools currently available, such as single mutant 
mice or synthetic peptides, are not powerful enough to fully ascertain PrPc, Dpl or Sho 
functions. Prion research is evolving daily and researchers need to develop new tools, 
such as conditional expression models of the truncated form of PrPc, together with 
extensive biochemical and morphological analysis to address these challenging 
questions. Within a few years it may be possible for us to determine the cues 
responsible for the current “ying and yang” (positive and negative) functions of PrPc. 
This will be an important step forward; however, we are still unable to determine the 
molecular cues responsible for the loss of basic brain functions in CJD patients and in 
prion-infected mice. Future studies are likely to reveal that the “ying and yang” 
phenomena of PrPc are also interconnected in CJD patients. 
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Figure Legends 
 
 
Figure 1 
 
Scheme of PrPc, Dpl and several N-terminal truncated forms of PrPc (F35, PrPCD and 
PrPCR). Overexpression of Dpl and truncated PrPc forms in absence of intrinsic PrPc 
promote neuronal degeneration and ataxia (see Section 3).  
 
Figure 2 
 
Scheme illustrating the recently reported data about, PrPc and A oligomer 
removal. 1) Normal traficking of the PrPc from lipid raft into the cell his mediated 
by Cu2+ and a co-receptor (Taylor and Hooper, 2007). Interaction with A 
oligomers (2) may modify the interaction of PrPc with i co-receptor leading to a 
putative endocytic process (3) (Lauren et al., 2009). However, whether this 
process takes place and A oligomers are degraded or is able to modify signal 
transduction as indicated warrant further study. In addition, a link between these 
interactions and tau phosphorylation is missing. Lastly, a putative interaction of 
PrPc with A oligomers to enhance fibril formation and A deposition could take 
place (4). 
 
Figure 3 
 
Scheme illustrating a putative scenario for PrPc and Sho in neuroprotection. In 
normal mice both proteins transducer neuroprotective signals (1). In prnp -/- 
mice, although PrPc is missing Sho is able to induce a decreased 
neuroprotective signal, and some modified phenotype is present in these mice 
(2). In PrPsc infected mice levels of Sho are reduced (Watts et al., 2007). 
Therefore the neurodegenerative process observed in infected animals may 
appear in the sum of factors among which we find the loss of neuroprotective 
function of PrPc and Sho joined with the neurodegenerative effect induced by 
the PrPsc (3). 
 
  
Figure 4 
 
Proposed models of  PrPc/receptor interaction. A) Scheme proposed by Baumann and 
coworkers which suggests that PrPCD interaction with a putative PrPc receptor could 
trigger neuronal degeneration. This interaction could play as a stabilized dominant 
negative (adapted from Baumann et al., 2007). B) Model suggested by Li and 
coworkers for PrPCR form. PrPCR activates a putative PrPc receptor in a “pathological” 
manner, transducing an exacerbated death signal. PrPCR, as proposed, has more 
interaction affinity for PrPc receptor that intrinsic PrPc (adapted from Li et al., 2007).      
 
